NEW YORK, June 30, 2026, 14:01 EDT
- UiPath, Inc. NYSE:PATH ticked up roughly 0.5% in the latest trade, trailing the Invesco QQQ Trust Series 1 NASDAQ:QQQ, which gained around 1.6%.
- UBS cut its target to $12 from $13 on June 29, and the move kept pressure on the stock. The company’s recent filings showed it still has buyback capacity of about 7% of market value.
- UiPath’s Q2 ARR outlook points to around $28 million to $33 million in additional ARR from April 30 to July 31, which is down from the $49 million in net new ARR it posted in Q1.
UiPath, Inc. NYSE:PATH ticked higher in Tuesday’s session, though the move lagged a wider run in big software and tech stocks. Shares were seen trading at $10.735, up 5.5 cents over the previous close. Volume crossed 35 million shares. Market cap stood near $5.67 billion. PATH still rests more on capital-return hopes than a clear growth shift.
The New York Stock Exchange was open for its main trading session at the dateline. Regular hours run from 9:30 a.m. to 4:00 p.m. ET. June 30 is a normal trading day in 2026, not a holiday. The NYSE will close next on July 3 for the Independence Day holiday.
| Instrument | Latest level/price | Change | Read-through |
|---|---|---|---|
| UiPath, Inc. NYSE:PATH | $10.735 | +0.5% | PATH is up, but trailing tech |
| SPDR S&P 500 ETF Trust (NYSEARCA:SPY) | $746.48 | +0.7% | Buyers still in broad market |
| Invesco QQQ Trust Series 1 NASDAQ:QQQ | $736.01 | +1.6% | Big tech outpacing PATH again |
The index comparison matters because UiPath is still priced like investors want proof its AI automation pitch can deliver steadier ARR growth. UBS analyst Radi Sultan kept a Neutral on June 29 and cut the target to $12 from $13, GuruFocus said. Benzinga carried the same UBS $12 target drop as of June 29.
The key point is the gap between UiPath’s share repurchase authorization and its ARR. UiPath’s June 4 quarterly filing showed $436.9 million left in buyback power as of April 30. The company bought another 2.4 million shares from May 1 to May 15 for an average of $9.63 per share. That works out to about $414 million still available for buybacks after May 15, or about 7.3% of Tuesday’s market cap.
| Measure | Data point | Investor read |
|---|---|---|
| April 30 liquidity | $1.416 billion | This is about 25% of the market cap right now |
| ARR at April 30 | $1.901 billion | Marks the FY27 growth starting line |
| Q2 ARR guide | $1.929 billion-$1.934 billion | Suggests a gain of around $28 million to $33 million |
| Q1 net new ARR | $49 million | Q2 guide would come in lower than Q1 |
| Estimated buyback left after May 15 | About $414 million | At latest price, that’s roughly 38.5 million shares |
UiPath posted first-quarter revenue of $418.4 million, a 17% increase, with ARR reaching $1.901 billion, up 12% for the quarter ended April 30. The company sees second-quarter revenue between $395 million and $400 million, and expects ARR of $1.929 billion to $1.934 billion as of July 31.
That ARR step-down is a big reason the stock hasn’t traded like a clear AI winner, even with the large cash position. At April 30, the company reported $1.4157 billion in cash, cash equivalents and marketable securities, and cash flow from operations of $131.9 million for the quarter. But according to the same filing, cash has gone to acquisitions and share repurchases, and future buybacks are discretionary.
UiPath’s June 29 8-K didn’t bring much in the way of fresh operating numbers. The company reported in its annual meeting filing that all seven board members were re-elected, the say-on-pay proposal was approved, and KPMG was ratified as auditor for the fiscal year ending Jan. 31, 2027. Voters representing 93.78% of voting power took part.
June 29 Form 4s show these were just standard director equity awards, not open-market purchases. Philippe Botteri, Karenann Terrell, Daniel Springer, Michael Gordon, Richard P. Wong, and June Yang all got 19,175 RSUs each for $0, as part of the non-employee director comp plan.
UiPath CEO Daniel Dines called it a “strong start to the fiscal year” in the company’s May earnings release. Dines said the new agentic products are “moving from pilot to production.” COO and CFO Ashim Gupta said results were “exceeding our guidance,” citing “continued operational discipline.” UiPath, Inc.
UiPath’s investor calendar doesn’t show any events after the June 25 annual meeting. So shares will likely trade off whether ARR at the end of July lands inside the $1.929 billion-$1.934 billion range the company guided, not on any near-term presentations. Buyback activity could also be a factor.
